Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

This study is testing a CAR-T cell therapy called brexucabtagene autoleucel as a consolidation treatment for adults with B-cell acute lymphoblastic leukemia (ALL) — a blood cancer — after initial chemotherapy has reduced the disease. **You may be eligible if...** - You are 18 or older with relapsed or refractory B-cell ALL - OR you have newly diagnosed high-risk B-cell ALL with specific genetic features - Your leukemia cells express the CD19 marker (more than 50% positive) - Your organ function (kidneys, liver, bilirubin) is within acceptable limits **You may NOT be eligible if...** - Your leukemia cells do not express CD19 - You have uncontrolled viral infections (e.g., Hepatitis B or C, HIV) - Your organ function is too poor to tolerate this therapy - You have had a prior CAR-T cell treatment targeting CD19 Talk to your doctor to see if this trial is right for you.